Role of puerarin in pathological cardiac remodeling: A review

Lv, Jiayu; Shi, Shuqing; Zhang, Bingxuan; Xu, Xia; Zheng, Haoran; Li, Yumeng; Cui, Xiangning; Wu, Huaqin; Song, Qingqiao

doi:10.1016/j.phrs.2022.106152

Cited by 30 publications

(16 citation statements)

References 187 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…48 In animal models of ventricular remodelling after acute myocardial infarction, up-regulation of VEGFA expression reduces left ventricular remodelling and improves cardiac function. 49 Increased expression of angiogenic factor VEGFA also improves microvascular formation and oxygen diffusion, thereby alleviating cardiac fibrosis and myocardial remodelling. 50 Studies have also demonstrated that angiogenesis is regulated by histone acetylation modification.…”

Section: Discussionmentioning

confidence: 99%

SIRT6 mediated histone H3K9ac deacetylation involves myocardial remodelling through regulating myocardial energy metabolism in TAC mice

Wu,

Zhang,

Peng

et al. 2023

J Cellular Molecular Medi

View full text Add to dashboard Cite

Pathological myocardial remodelling is the initial factor of chronic heart failure (CHF) and is induced by multiple factors. We previously demonstrated that histone acetylation is involved in CHF in transverse aortic constriction (TAC) mice, a model for pressure overload‐induced heart failure. In this study, we investigated whether the histone deacetylase Sirtuin 6 (SIRT6), which mediates deacetylation of histone 3 acetylated at lysine 9 (H3K9ac), is involved pathological myocardial remodelling by regulating myocardial energy metabolism and explored the underlying mechanisms. We generated a TAC mouse model by partial thoracic aortic banding. TAC mice were injected with the SIRT6 agonist MDL‐800 at a dose of 65 mg/kg for 8 weeks. At 4, 8 and 12 weeks after TAC, the level of H3K9ac increased gradually, while the expression of SIRT6 and vascular endothelial growth factor A (VEGFA) decreased gradually. MDL‐800 reversed the effects of SIRT6 on H3K9ac in TAC mice and promoted the expression of VEGFA in the hearts of TAC mice. MDL‐800 also attenuated mitochondria damage and improved mitochondrial respiratory function through upregulating SIRT6 in the hearts of TAC mice. These results revealed a novel mechanism in which SIRT6‐mediated H3K9ac level is involved pathological myocardial remodelling in TAC mice through regulating myocardial energy metabolism. These findings may assist in the development of novel methods for preventing and treating pathological myocardial remodelling.

show abstract

Section: Discussionmentioning

confidence: 99%

SIRT6 mediated histone H3K9ac deacetylation involves myocardial remodelling through regulating myocardial energy metabolism in TAC mice

Wu,

Zhang,

Peng

et al. 2023

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…Puerarin can be used to treat coronary heart disease, angina pectoris, and hypertension (Ma et al, 2022;Shao et al, 2022). Puerarin treatment causes an expansion of coronary blood vessels and cerebral blood vessels, improves local blood flow, improves microcirculation, inhibits platelet aggregation, reduces muscle oxygen consumption, and increases oxygen supply (Zeng et al, 2021;Lv et al, 2022).…”

Section: Single Tcm Extract Injectionmentioning

confidence: 99%

Chinese herbal injection for cardio-cerebrovascular disease: Overview and challenges

et al. 2023

View full text Add to dashboard Cite

Cardio-cerebrovascular diseases are the leading cause of death worldwide and there is currently no optimal treatment plan. Chinese herbal medicine injection (CHI) is obtained by combining traditional Chinese medicine (TCM) theory and modern production technology. It retains some characteristics of TCM while adding injection characteristics. CHI has played an important role in the treatment of critical diseases, especially cardio-cerebrovascular diseases, and has shown unique therapeutic advantages. TCMs that promote blood circulation and remove blood stasis, such as Salvia miltiorrhiza, Carthami flos, Panax notoginseng, and Chuanxiong rhizoma, account for a large proportion of CHIs of cardio-cerebrovascular disease. CHI is used to treat cardio-cerebrovascular diseases and has potential pharmacological activities such as anti-platelet aggregation, anti-inflammatory, anti-fibrosis, and anti-apoptosis. However, CHIs have changed the traditional method of administering TCMs, and the drugs directly enter the bloodstream, which may produce new pharmacological effects or adverse reactions. This article summarizes the clinical application, pharmacological effects, and mechanism of action of different varieties of CHIs commonly used in the treatment of cardio-cerebrovascular diseases, analyzes the causes of adverse reactions, and proposes suggestions for rational drug use and pharmaceutical care methods to provide a reference for the rational application of CHIs for cardio-cerebrovascular diseases.

show abstract

“…In addition, salubrinal, an ER stress inhibitor, alleviates MI/RI by selectively inhibiting eIF2-alpha dephosphorylation, which results in inhibition of ER stress [ 99 , 100 ] , thereby providing another potential therapeutic strategy for the prevention of MI/RI. Furthermore, puerarin, an isoflavone extracted from the kudzu root, is used as a conventional cardiovascular drug in countries in eastern Asia [101] . Puerarin has been shown to improve end-stage CVD (HF) by inhibiting myocyte loss and ferroptosis [59] .…”

Section: Ferroptosis Intervention In Cvdsmentioning

confidence: 99%

Multifaceted role of ferroptosis in cardiovascular disease

Li¹,

Zhu²,

Chen³

et al. 2023

ABBS

View full text Add to dashboard Cite

Ferroptosis is a newly identified form of non-apoptotic cell death characterised primarily by iron-dependent lipid peroxidation. It differs morphologically, biochemically, and genetically from other forms of cell death, such as apoptosis, autophagy, and necrosis. Although the molecular mechanism underlying ferroptosis remains unclear, multiple biological processes, such as iron metabolism, lipid peroxides, and systems, such as the glutathione system and the tetrahydrobiopterin/coenzyme Q10 system, appear to be involved. While the contribution of ferroptotic mechanisms to human diseases is not clear, recent studies have identified a number of ferroptosis-related genes. Cardiovascular diseases are the main cause of death globally. In this review, we outline the progress regarding the emerging role of ferroptosis in the pathogenesis of cardiac pathophysiological conditions and the association of ferroptosis with cardiomyopathy, myocardial ischemia-reperfusion injury, heart failure, and atherosclerosis. We further summarise newly discovered ferroptotic targets for the development of therapies for cardiovascular diseases. Finally, we discuss the current challenges and future research directions in cardiovascular disease treatments.

show abstract

Role of puerarin in pathological cardiac remodeling: A review

Cited by 30 publications

References 187 publications

SIRT6 mediated histone H3K9ac deacetylation involves myocardial remodelling through regulating myocardial energy metabolism in TAC mice

SIRT6 mediated histone H3K9ac deacetylation involves myocardial remodelling through regulating myocardial energy metabolism in TAC mice

Chinese herbal injection for cardio-cerebrovascular disease: Overview and challenges

Multifaceted role of ferroptosis in cardiovascular disease

Contact Info

Product

Resources

About